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ABSTRACT  
Objective: This paper describes development and validation of a high-performance liquid chromatographic analytical procedure for simultaneously 
determination of metronidazole and ciprofloxacin in a model tablet formulations.  
Methods: The separation was achieved with a LiChrosorb® RP-18 (250 x 4.6 mm) column, at 33 °C temperature with isocratic mode and a mobile phase 
containing triethylamine: o-phosphoric acid and аcetonitrile (0.02:80:20 v/v/v). The flow rate was 1.0 ml/min and the eluent was monitored at 290 nm.  
Results: The selected chromatographic conditions were found to separate effectively metronidazole and ciprofloxacin with a retention time of 3.46 
min and 6.68 min, respectively. The method was validated for analytical parameters specificity, linearity, precision, accuracy, LOD and LOQ. The 
calibration curves were linear in the concentration range of 12.5-100.0 µg/ml for metronidazole and ciprofloxacin. The recovery for metronidazole 
and ciprofloxacin was 100.1 % and 100.2 %, respectively.  
Conclusion: The analytical procedure was applied to quality control of model tablet formulations. It was established that the developed analytical 
procedure was successfully used for routine analysis of metronidazole and ciprofloxacin in model tablet dosage forms without any interference 
from included excipients.  
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(piperazinyl)-quinolone-3-carboxylic acid] is a second generation 
fluoroquinolone antibacterial agent. Its spectrum of activity includes 
most strains of Gram-positive and Gram-negative bacterial pathogens 
responsible for respiratory, urinary tract, gastrointestinal and abdominal 
infections [1]. Because of its low toxicity, very wide spectrum of 
antibacterial effect and low ability to cause bacterial resistance, CIP has 
been widely used in clinical practice [2]. Metronidazole (MET) [2-
methyl-5-nitroimidazole-1-ethanol] is an antiprotozoal, antiamebic and 
antibacterial drug [3]. CIP has a reduced activity against anaerobic 
pathogens. Therefore, a combination of CIP with an antimicrobial agent 
active against anaerobes, such as MET, seems to be interesting for the 
treatment of mixed aerobic/anaerobic infections [4]. 
A survey of literature revealed several analytical methods for the 
simultaneous determination of CIP and MET in tablet forms and 
intravenous admixtures. The reported procedures included reversed-
phase high-performance liquid chromatography, thin-layer 
chromatography, UV-spectrophotometry, nuclear magnetic resonance 
spectrometry [5-17].  
Literature survey shows that the most HPLC methods for 
determination of CIP and MET in the mixture are based on a 
separation with mobile phases including phosphate buffer (variety 
of pH values and concentration) and organic diluents in different 
ratios [8-11]. The use of phosphate salts should be avoided to ensure 
correct and trouble-free exploitation of HPLC system. In our study, 
the separation was achieved without the usage of any phosphate 
buffer salts, which we appreciate as an advantage of the so 
presented analytical method. 
In this article, a rapid, specific and accurate RP-HPLC method have 
been described for the simultaneous determination of both drugs in 
model tablet formulations. 
MATERIALS AND METHODS  
Materials and chemicals  
MET and CIP reference standards were obtained from Sigma-Aldrich. 
HPLC grade acetonitrile was procured from Merck Ltd. Different model 
tablet formulations containing MET 250 mg and CIP 250 mg was 
prepared. Microcrystalline cellulose (type Vivapur 101®, JRS Pharma-
Germany), maize starch (Roquette Pharma-France), lactose 
monohydrate (Meggle Pharma-Germany), carboxymethylcellulose 
sodium, cross-linked (Vivasol®, JRS Pharma-Germany), povidone 
(Kollidone® K30, BASF–Germany), magnesium stearate and silica 
colloidal anhydrous (Aerosil® 200, Evonik Ind.) were used as excipients. 
All other chemical reagents were of analytical grade.  
Instrumentation and chromatographic conditions  
HPLC analysis was performed by isocratic elution with a flow rate 
1.0 ml/min. A high performance liquid chromatographic system 
(SHIMADZU Corporation, LC-20 AD quaternary pump) with an 
autosampler, Shimadzu DGU-20A5 vacuum degasser, and a 
Shimadzu SPD-20A UV/VIS detector was used for analysis.  
 
 
Fig. 1: Typical chromatogram of MET and CIP 
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The data was recorded using Lab Solutions Software. Separation was 
carried out at 33 °C, using LiChrosorb®RP-18 (250 x 4.6 mm) column 
packed with octadecylsilyl silica gel 5 μm. The detector was set at 
290 nm. The mobile phase was prepared by mixing of triethylamine: 
o-phosphoric acid and аcetonitrile (0.02:80:20 v/v/v). The mobile 
phase was sonicated for 10 min and then it was filtered through a 
0.45 μm filter paper. The chromatographic conditions were found to 
yield good separation with a retention time of 3.46 min for MET and 
6.68 min for CIP with sharp symmetrical peak. The chromatogram is 
shown in fig. 1. 
Preparation of standard solution  
50 mg of MET and 50 mg CIP working standards (accurately 
weighed) were transferred into a 100 ml volumetric flask. After 
addition of about 70 ml solvent A (prepared by mixing of 80 ml 0.3% 
o-phosphoric acid solution and 20 ml acetonitrile), the mixture was 
sonicated for about 2 min and after made up to the volume. The 
stock solution was suitably diluted to produce a concentration of 
0.05 mg/ml of MET and 0.05 mg/ml of CIP respectively.  
Sample preparation  
Twenty tablets were weighed, finely powdered and the average 
weight was determined. A portion of powder equivalent to 250 mg 
MET and 250 mg CIP is transferred into 50 ml volumetric flask and 
25 ml of solvent A was added and sonicated for 10 min to effect 
complete dissolution of both substances. The suspension was then 
made up to volume with solvent A and after filtered. The aliquot 
portion of the filtrate was further diluted to get a final concentration 
of 50 μg/ml of MET and 50 μg/ml of CIP. 20 μl of the test solution 
were injected, chromatogram was recorded, and the amounts of the 
drugs were calculated.  
Preparation of model tablets  
Model tablets containing 250 mg MET and 250 mg CIP were 
prepared by compression after wet granulation with a single punch 
tablet press (EK 0, Korsch, Berlin, Germany) with a set of 13 mm 
diameter standard concave tooling.  
Determination of mechanical strength of the tablets  
It was performed by the method of the progressive loading 
according to Eur. Ph. 8.0, apparatus-Erweka type TBH 30, Germany.  
Determination of friability  
It was performed according to Eur. Ph. 8.0 in friabilitor Erweka TAR 
20, Germany.  
Disintegration time  
It was performed by the method described in Eur. Ph. 8.0 in water, 
using apparatus Erweka ZT 3, Germany. 
In vitro drug dissolution studies  
Drug release profiles were evaluated using a dissolution test 
apparatus (Еrweka DT 600, Hensenstmm, Germany). The test was 
carried out at a paddle rotation speed of 50 rpm, maintained at 
37±0.5 °C, in 900 ml dissolution medium at 1.2 pH value. The 
dissolution progress was monitored by withdrawing 5 ml filtered 
samples (0.45 μm filter) at preselected intervals (up to 60 min). The 
quantity of MET and CIP in sample solutions was analyzed by 
described method. The cumulative percentage of drug release was 
calculated, and the average of six determinations was used in the 
data analysis.  
RESULTS AND DISCUSSION  
To optimize the RP-HPLC parameters, several mobile phase 
combinations were studied. Mobile phases containing acetonitrile 
and o-phosphoric acid solution (40:60; 30:70; 20:80; 10:90 v/v) 
were examined. In addition, the effects of the flow rate of the mobile 
phase (0.5–1.0 ml/min) and column temperature (25-40 °C) were 
checked. A satisfactory separation in suitable run time and good 
peak symmetry were found in a mixture of triethylamine: o-
phosphoric acid and аcetonitrile (0.02:80:20 v/v/v) at flow rate 1 
ml/min proved to be better than the other mixtures in terms of 
resolution and peak shape. The optimum wavelength for detection 
was set at 290 nm at which detector responses obtained were much 
better for both drugs. As shown in fig. 1, the retention times were 
3.46 min for MET and 6.68 min for CIP. The developed method for 
determination of MET and CIP was further validated according to 
ICH guidelines as follows [18].  
Selectivity  
Selectivity of the current method was demonstrated by good 
separation of both active ingredients (MET and CIP). Furthermore, 
matrix components, e. g. excipients, do not interfere with the two 
analytes. 
Linearity  
Standard solutions containing MET (12.5-100 µg/ml) and CIP (12.5-
100 µg/ml) were prepared in the solvent A. Triplicate 20 µl 
injections were made for each standard solution to estimate the 
reproducibility of the detector response at each concentration level 
and chromatographed under the conditions described above. The 
area of each peak was plotted against the concentration to obtain the 
calibration graphs (fig.2 and 3).  
 
 
Fig. 2: Linearity graph of MET 
 
 
Fig. 3: Linearity graph of CIP 
 
The five concentrations of each compound were subjected to 
regression analysis to calculate the calibration equation and 
correlation coefficients. The results obtained are shown in the tables 
1-2. The described method was linear for the two analytes in the 
range specified above with a correlation coefficients better than 
0.999. 
Limit of detection (LOD) and limit of quantitation (LOQ)  
LOD and LOQ were experimentally verified by six injections of MET 
and CIP at the appropriate concentrations. The LOD was calculated 
to be 0.012 and 0.04 µg/ml and the LOQ was calculated to be 0.125 
and 0.4 µg/ml for MET and CIP, respectively.  
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The system precision of this method was evaluated by calculating 
the %RSD of the peak areas of six replicate injections of the standard 
solution, which were found to be 0.39% for MET and 0.37% for CIP. 
For method precision evaluated with six sample replicate injections 
were found to be 0.41% and 0.39% for MET and CIP respectively 
and it was found to be less than 1.0% shown in the table 3. 
 
Table 1: Linearity data for MET 
























Table 2: Linearity data for CIP 
























Table 3: Results of precision for MET and CIP 
 MET CIP 
System precision % RSD  






Table 4: Results of % recovery studies for MET and CIP 
Sample Recovery Amount present, mg Amount recovered, mg % recovered SD* %RSD 




































*average value of three determinations 
 
Table 5: Model tablet compositions 
Composition  Model MC1 (g) Model MC2 (g) 
MET 0.250 0.250 
CIP 0.250 0.250 
Microcrystalline cellulose 0.050 0.050 
Maize starch 0.100 - 
Lactose monohydrate - 0.070 
Carboxymethylcellulose sodium, cross-linked - 0.030 
Magnesium stearate 0.007 0.007 
Silica colloidal anhydrous 0.003 0.003 
Povidone  0.006 0.005 
Model tablet characteristics 
Uniformity of mass of tablets, g 0.666±5% 0.665±5% 
Mechanical strength, N 50-60 50-55 
Friability, % 0.5 0.4 
Disintegration time, min 1 3 
 
Maslarska et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 5, 306-310 
 
309 








































Fig. 4: In vitro MET and CIP release profiles from developed model tablet formulations (n=6): a-model MC 1 and b-model MC 2 
 
Accuracy  
The accuracy of the method was calculated by recovery studies. It is 
carried out by preparing the samples of 50%, 100% and 150% of 
target concentration. The samples were prepared in triplicate in 
each level. The results of studies along with its evaluation are given 
in the table 4. 
Obtaining of model tablet compositions 
Model tablet formulations and characteristics of tablets are 
presented in table 5. 
In vitro drug dissolution studies 
Data from the MET and CIP release studies from models MC1 and MC2 
at pH 1.2 are presented in fig. 4.As seen from the data presented in fig. 
4 the rate of both drugs release is faster in model MC1 in comparison 
with Model MC2, especially in the beginning of the process. Model MC1 
released 92% MET and 81% CIP for 30 min, while the model MC2 
reaches 82% MET and 75% CIP for the same period. Over 80% CIP 
release from model MC2 is observed at 45 min.  
CONCLUSION  
An accurate, sensitive and precise HPLC method with UV detection 
for the simultaneous estimation of MET and CIP was developed and 
validated for quality control analysis in combined tablets. This 
method is also applicable for the determination of the above drugs 
separately in other formulations. The proposed method is rapid, 
where the total analytical run time for both drugs are less than 8 min 
and shows a high degree of accuracy and precision with less than 2 
% RSD. It is convenient for laboratory quality control of tablet 
dosage forms containing both substances.  
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